Current status and future prospects of yellow fever vaccines. (2nd November 2015)

• Record Type: Journal Article
• Authors: Beck, Andrew S; Barrett, Alan DT
• Is Part Of: Expert review of vaccines. Volume 14:Number 11(2015)
• Page Start: 1479
• Page End: 1492
• Publication Date: 2015-11-02
• Subjects: empiric -- empiric vaccine -- flavivirus -- live-attenuated -- primary seed -- rational vaccine -- recombinant vaccine -- secondary seed -- vaccine -- viral diversity -- yellow fever virus; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2015.1083430
• Languages: English
• ISSNs: 1476-0584

Abstract

Abstract : Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. These unique properties of 17D are presently exploited in rationally designed recombinant vaccines targeting not only flaviviral antigens but also other pathogens of public health concern. Several candidate vaccines based on 17D have advanced to human trials, and a chimeric recombinant Japanese encephalitis vaccine utilizing the 17D backbone has been licensed. The mechanism(s) of attenuation for 17D are poorly understood; however, recent insights from large in silico studies have indicated particular host genetic determinants contributing to the immune response to the vaccine, which presumably influences the considerable durability of protection, now in many cases considered to be lifelong. The very rare occurrence of severe adverse events for 17D is discussed, including a recent fatal case of vaccine-associated viscerotropic disease.